Abstract
Response to immune checkpoint inhibitors depends on tumor intrinsic properties and also on host factors in the tumour microenvironment including the presence of immune cells (IC). We hypothesized that nivolumab efficacy varies across different metastatic sites. We retrospectively analyzed computed tomography scans of patients with metastatic non-small cell lung carcinoma (NSCLC) receiving nivolumab. RECIST 1.1 criteria were applied to assess the overall response rate (ORR) and organ-specific response rate (OSRR). We analyzed 52 patients including 44% females, 58% adenocarcinoma and 8% never smokers. Involved organs had target-lesions in the lung (42%), liver (25%), lymph nodes (56%) and soft tissue (13%) and non-target lesions in the bones (23%). ORR and disease control rate (DCR) were 20% and 45%, respectively. Median overall survival, progression-free survival and duration of response were 11.9, 2.3 and 10.3 months. OSRR and organ-specific DCR (OSDCR) were 28% and 90% in lymph nodes, 8% and 54 in the liver, and 9% and 55% in lung metastases. Nine out of 12 patients with bone metastases had progressive lesions. The cumulative incidence probability of organ-specific progression at 6 months was 14% in lymph nodes, 42% in the liv...Continue Reading
References
Jan 18, 2003·Endocrine Research·S R Bornstein, H Rutkowski
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Nov 17, 2012·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Andrew J WeickhardtD Ross Camidge
Apr 23, 2013·Cellular & Molecular Immunology·Fenglei Li, Zhigang Tian
Nov 28, 2014·Nature·Paul C TumehAntoni Ribas
Dec 19, 2014·Nature Immunology
Dec 30, 2014·Molecular and Cellular Endocrinology·Waldemar KanczkowskiStefan R Bornstein
Feb 20, 2015·Molecular Cancer Therapeutics·Sandip Pravin Patel, Razelle Kurzrock
Mar 15, 2015·Science·Naiyer A RizviTimothy A Chan
Apr 4, 2015·Science·Padmanee Sharma, James P Allison
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel
Aug 15, 2015·Cancer Discovery·Antoni Ribas
Sep 29, 2015·The New England Journal of Medicine·Hossein BorghaeiJulie R Brahmer
Oct 21, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M IlieP Hofman
Mar 14, 2016·Lancet·Louis FehrenbacherUNKNOWN POPLAR Study Group
Oct 25, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Klazien Matter-WalstraUNKNOWN Swiss Group for Clinical Cancer Research
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Dec 27, 2016·Journal for Immunotherapy of Cancer·Mizuki NishinoMark M Awad
Jan 20, 2017·Nature·Daniel S Chen, Ira Mellman
Apr 12, 2017·Nature·Alexander C HuangE John Wherry
Apr 16, 2017·Cancer Immunology Research·Paul C TumehAdil Daud
May 30, 2017·The Lancet Oncology·Narek ShaverdianPercy Lee
Jun 22, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P N AguiarG L Lopes
Sep 13, 2017·Cancer Immunology, Immunotherapy : CII·Stefan DiemLukas Flatz
Citations
Jan 24, 2019·Cancers·Jessica CusatoAntonio D'Avolio
Dec 1, 2019·Investigational New Drugs·Hayato KawachiToru Kumagai
Jun 2, 2020·Expert Review of Anticancer Therapy·Maddalena DoniniMatteo Santoni
Aug 12, 2020·Thoracic Cancer·Xing LiChunxia Su
Nov 23, 2019·Journal for Immunotherapy of Cancer·Lorenza LandiFederico Cappuzzo
Jul 1, 2020·Future Oncology·Yong-Jin KimSusan Horton
Aug 1, 2020·Frontiers in Oncology·Kaili YangLin Zhao
Apr 29, 2020·Cancers·Stephan RheinheimerPetros Christopoulos
Oct 4, 2020·Science Immunology·James C LeeJeffrey A Bluestone
May 20, 2020·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·V FormicaH T Arkenau
Nov 17, 2020·Frontiers in Oncology·Anita J W M BrounsLizza E L Hendriks
Nov 17, 2020·Frontiers in Oncology·Sergi BenaventeJuan Lorente
Jan 8, 2021·Cancer Immunology, Immunotherapy : CII·Hong-Ming TsaiHsin-Yu Kuo
Feb 3, 2021·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Florian EichhornMartin E Eichhorn
Oct 30, 2020·Research and Reports in Urology·Nobuki FurubayashiMotonobu Nakamura
Jul 23, 2020·Clinical Genitourinary Cancer·Francesco MassariLaurence Albiges
Mar 30, 2021·OncoTargets and Therapy·Nobuki FurubayashiMotonobu Nakamura
Apr 6, 2021·Frontiers in Oncology·Hyunjong LeeHongyoon Choi
Feb 17, 2021·Cancer Research·Jiawei ZhouYanguang Cao
Jun 3, 2021·Cancers·Ling PengZibing Wang
Jun 10, 2021·Expert Opinion on Investigational Drugs·D Brock HewittTimothy M Pawlik
Aug 10, 2021·JAMA Network Open·Chongkai WangMarwan Fakih
Apr 21, 2021·Journal of the National Comprehensive Cancer Network : JNCCN·Angel QinDwight H Owen
Feb 27, 2020·Oncology Research and Treatment·Hsin-Yu KuoYih-Jyh Lin
Dec 19, 2020·Journal for Immunotherapy of Cancer·Galam LeemSu-Hyung Park
Jan 7, 2022·Annals of Surgical Oncology·Lauren N KrumeichHeather Wachtel
Jan 15, 2022·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Einat Cinnamon, Eli Pikarsky